Keros Therapeutics (KROS)

$

9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
.
9
8
7
6
5
4
3
2
1
0
0
+$5.22 (+8.08%)Past DayToday's Volume:
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
,
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0
9
8
7
6
5
4
3
2
1
0
0

About

Business overview of Keros Therapeutics (KROS)
Keros Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel treatments for patients suffering from hematological, pulmonary, and cardiovascular disorders with high unmet medical needs. The company's protein therapeutic product candidate, KER-050, is being developed for the treatment of low blood cells counts, or cytopenias, including anemia and thrombocytopenia, in patients with myelodysplastic syndromes, or MDS, and in patients with myelofibrosis.

Key Insights

Critical company metrics and information
  • Share Price

    $70.00
  • Market Cap

    $2.84 Billion
  • Total Outstanding Shares

    40.51 Million Shares
  • Total Employees

    160
  • Dividend

    No dividend
  • IPO Date

    April 8, 2020
  • SIC Description

    Pharmaceutical Preparations
  • Homepage

    https://www.kerostx.com

Historical Stock Splits

Execution DateSplit Amount
No Historical Stock Splits

Cash Flow Statement

October 1, 2023 to September 30, 2024
MetricValue
Net Cash Flow, Continuing$243.03 Million
Net Cash Flow From Financing Activities$385.53 Million
Net Cash Flow From Investing Activities, Continuing$-2.18 Million
Net Cash Flow From Operating Activities, Continuing$-140.32 Million
Net Cash Flow From Investing Activities$-2.18 Million
Net Cash Flow From Financing Activities, Continuing$385.53 Million
Net Cash Flow From Operating Activities$-140.32 Million
Net Cash Flow$243.03 Million

Income Statement

October 1, 2023 to September 30, 2024
MetricValue
Research and Development$165.49 Million
Net Income/Loss Available To Common Stockholders, Basic$-181.57 Million
Net Income/Loss$-181.57 Million
Diluted Earnings Per Share$5.22
Net Income/Loss Attributable To Noncontrolling Interest$0.00
Diluted Average Shares$36.69 Million
Benefits Costs and Expenses$153.14 Million
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic$0.00
Nonoperating Income/Loss$22.46 Million
Basic Average Shares$36.69 Million
Revenues$651000.00
Net Income/Loss Attributable To Parent$-181.57 Million
Operating Income/Loss$-204.03 Million
Preferred Stock Dividends And Other Adjustments$0.00
Income/Loss From Continuing Operations Before Tax$-152.49 Million
Other Operating Expenses$39.19 Million
Income/Loss From Continuing Operations After Tax$-181.57 Million
Basic Earnings Per Share$5.22
Costs And Expenses$187.74 Million
Operating Expenses$204.69 Million

Balance Sheet

October 1, 2023 to September 30, 2024
MetricValue
Liabilities And Equity$579.27 Million
Equity Attributable To Noncontrolling Interest$0.00
Assets$579.27 Million
Wages$8.03 Million
Current Assets$552.05 Million
Current Liabilities$29.01 Million
Noncurrent Liabilities$17.43 Million
Noncurrent Assets$27.23 Million
Liabilities$46.44 Million
Accounts Payable$4.98 Million
Equity Attributable To Parent$532.84 Million
Other Current Liabilities$16.00 Million
Equity$532.84 Million
Fixed Assets$4.37 Million
Other Non-current Assets$22.86 Million

Historical Dividends

Announcement DatePayment DateRecord DateAmountFrequency
No historical dividends
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.